Mindfulness-Based Pain Management (MBPM) for Patients With Chronic Musculoskeletal Pain

December 2, 2022 updated by: Holger Cramer, Universität Duisburg-Essen

Mindfulness-Based Pain Management (MBPM) for Patients With Chronic Musculoskeletal Pain: a Randomized Controlled Trial.

Mindfulness-Based Pain Management (MBPM) is an eight-week behavioral medicine program. Based on the well-known Mindfulness-Based Stress Reduction (MBSR) program, it was specifically developed as an intervention for chronic pain. During the program, mindfulness exercises, gentle body exercises and body awareness and breathing exercises, as well as pain regulation methods are taught.

Initial studies suggest efficacy of the program with regard to chronic pain, however, the effect of the standardized program in patients with chronic musculoskeletal pain has not yet been investigated in a clinical study. Therefore, the aim of this study is to investigate the MBPM program on pain acceptance in patients with chronic musculoskeletal pain. To this end, 40 patients with chronic (specific and non-specific) musculoskeletal pain will be randomly assigned to two study conditions. The intervention group will receive MBPM sessions of 150 minutes once a week over the course of 8 weeks, while the control group will receive standard therapy (waiting list). We hypothesize that patients will indicate a significantly higher pain acceptance after completing the program compared to patients not participating in the program.

Study Overview

Status

Completed

Conditions

Detailed Description

The purpose of this study is to investigate the efficacy of a structured 8-week Mindfulness-Based Pain Management (MBPM) program, based on the Breathworks method by Vidyamala Burch, in addition to standard therapy compared to standard therapy alone in terms of pain acceptance in patients with chronic musculoskeletal pain.

The study is a monocentric, single-blinded (data collector), randomized study with 2 study arms. Study center is the Clinic for Natural and Integrative Medicine, Evang. Kliniken Essen-Mitte.

Patients will be recruited via study calls on the clinic website as well as via press advertisements (see appendix). In addition, former patients who have been treated at the Clinic for Natural and Integrative Medicine for chronic musculoskeletal pain will be contacted. If a patient reports interest in the study, he/she will first be screened by telephone for the presence of the inclusion and exclusion criteria. In case of potential eligibility, patients are invited to the Study Center. All patients will be informed by a study physician and assessed for suitability to participate in the study.

The inclusion and exclusion criteria are assessed on site by the study physician by means of a detailed general medical history and an orienting clinical-neurological examination.

Eligible patients will be assigned to one of the two study arms after completion of measurements at week 0 via non-stratified block randomization with randomly varying block length. Establishing the randomization sequence and ensuring blinded assignment will be done via central randomization through RedCap software by an external researcher who will have no patient contact throughout the study. Neither the patients nor the study physician nor the study coordinators will have any insight into the randomization sequence.

The study has 3 defined measurement time points: A baseline measurement (week 0) before randomization, at which time all standardized questionnaires as well as patient-specific data on sociodemographics (age, height, gender, weight, socioeconomic status), lifestyle, duration of disease, previous and currently applied therapies will be asked, and further measurement time points at the end of the course 8 weeks after randomization (week 8) and 6 months after randomization (week 26).

The sample size calculation was based on a non-randomized study by Cusens et al (2010), which found a large effect size of d=1.04 for pain acceptance for MBPM in addition to standard therapy compared to standard therapy alone. Based on a power (1-) of 80%, a significance level of 5%, and an anticipated dropout rate of up to 20%, a 2-sided t-test requires a total sample size of 40 patients (20 patients per group) to detect such an effect.

All analyses are based on the intention-to-treat population, i.e., all patients enrolled in the study are evaluated in the group originally assigned to them regardless of the treatment actually received. Missing values will be replaced using standard imputation procedures.

The primary outcome parameter will be analyzed confirmatively using univariate analysis of covariance (ANCOVA), in which the main outcome parameter will be modeled as a function of group membership (binary co-variate), respective baseline values (linear covariate), and expectancy (linear covariate). Within this model, the adjusted group difference (including 95% confidence interval) is estimated and tested for superiority of the intervention over the control group using a two-sided t-test at the α=0.05 level. Secondary end points will be evaluated exploratively using the same models as the primary end point. Change scores (change scores) and effect sizes (hedges' g) for between-group comparisons will be calculated to assess the clinical significance of the results.

The influence of potential process variables will be investigated using multiple mediator analyses.

Study Type

Interventional

Enrollment (Actual)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Nordrhein-Westphalia
      • Essen, Nordrhein-Westphalia, Germany, 45276
        • Universität Duisburg-Essen

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

- Chronic specific or nonspecific musculoskeletal pain for at least 3 months

Exclusion Criteria:

New diagnosis within the last 3 months of:

  • Degenerative diseases (e.g., herniated disc, spinal stenosis)
  • Neurological diseases (e.g., neuropathies, multiple sclerosis)
  • Injuries of the spinal column (e.g. due to whiplash, vertebral body fractures, operations)

Or severe concurrent diagnosis of:

  • Severe comorbid mental illness (e.g. addiction, severe depression)
  • Severe comorbid physical illness (e.g. cancer diagnosis within the last 5 years, severe preexisting disease of the cardiovascular system, insufficiency of other organs (kidney, liver, etc.), acute febrile infection, other severe neurological diseases such as epilepsy)
  • Pregnancy
  • Current pension application (for work incapacity, occupational disability, reduction in earning capacity, severe disability)
  • Simultaneous participation in other clinical trials

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Mindfulness-based pain management
The program consists of sessions of 150 minutes once a week over the course of 8 weeks. Treatment as usual is allowed.
The structured program will include mindfulness exercises, meditation, a gentle body exercise series, and body awareness exercises, as well as information about pain, mindfulness-based pain management, and pain regulation methods suitable for everyday life. During the 8 weeks, treatment as usual is allowed.
Other Names:
  • Breathworks
No Intervention: Waiting-List
The control group will receive no active intervention in addition to treatment as usual during the study period.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
pain acceptance
Time Frame: week 8
Chronic Pain Acceptance Questionnaire, 20 items, range 0-6 with higher scores indicating a better outcome
week 8

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
pain acceptance
Time Frame: week 26
Chronic Pain Acceptance Questionnaire, 20 items, range 0-6 with higher scores indicating a better outcome
week 26
pain-associated self-efficacy
Time Frame: week 8 and 26
Arthritis Self-Efficacy Scale, 9 items, range 1-10 with higher scores indicating a better outcome
week 8 and 26
pain intensity
Time Frame: week 8 and 26
Numerical rating scale, range 0-10 with higher scores indicating a worse outcome
week 8 and 26
functional impairment
Time Frame: week 8 and 26
pain disability index, 7 items, range 0-10 with higher scores indicating a worse outcome
week 8 and 26
health-related quality of life
Time Frame: week 8 and 26
short form 12 with higher scores indicating a better outcome
week 8 and 26
psychiatric symptoms
Time Frame: week 8 and 26
Hospital Anxiety and Depression Scale,14 items, range 0-3 with higher scores indicating worse outcomes
week 8 and 26

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
mindfulness
Time Frame: week 8 and 26
Conscious Presence and Self Control Scale, 10 items, range 0-3 with higher scores indicating a better outcome
week 8 and 26
self-compassion
Time Frame: week 8 and 26
Self-Compassion Scale, 12 items, range 1-5 with higher scores indicating a better outcome
week 8 and 26
adverse events
Time Frame: week 8 and 26
documentation by trainer
week 8 and 26
treatment expectancy
Time Frame: week 0
Treatment Credibility Scale, 2 items, range 0-10 with higher scores indicating a better outcome
week 0
rationale credibility
Time Frame: week 8
Treatment Credibility Scale, 3 items, range 0-10 with higher scores indicating a better outcome
week 8

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Holger Cramer, PhD, Universität Duisburg-Essen
  • Principal Investigator: Heidemarie Haller, PhD, Universität Duisburg-Essen

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 21, 2022

Primary Completion (Actual)

July 31, 2022

Study Completion (Actual)

November 14, 2022

Study Registration Dates

First Submitted

January 5, 2022

First Submitted That Met QC Criteria

January 5, 2022

First Posted (Actual)

January 20, 2022

Study Record Updates

Last Update Posted (Actual)

December 5, 2022

Last Update Submitted That Met QC Criteria

December 2, 2022

Last Verified

December 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Pain

Clinical Trials on Mindfulness-based pain management

3
Subscribe